1953 In Malignant Fungating Wounds
04/09/2025 16:25
Sept 4 (Reuters) - Vyome Holdings Inc HIND.O: VYOME HOLDINGS INC: POSITIVE INTERIM DATA FROM PHASE 2 STUDY OF VT-1953 IN MALIGNANT FUNGATING WOUNDS VYOME HOLDINGS INC: VT-1953 CONTINUES TO SIGNIFICANTLY IMPROVE PRIMARY ENDPOINT Source text: ID:nBwxjBbCa Further company coverage: HIND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vyome Holdings
See all newsBrief: Vyome - Appoints Jerry Leonard As CFO On August 27, 2026 - SEC Filing
Biopharma firm Vyome Holdings posts Q2 net loss
Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity